Nothing Special   »   [go: up one dir, main page]

Candela et al., 1993 - Google Patents

Fibroblast growth factor increases TNFα-mediated prostaglandin E 2 production and TNFα receptor expression in human fibroblasts

Candela et al., 1993

Document ID
14184825702489074244
Author
Candela M
Barker S
Ballou L
Publication year
Publication venue
Molecular and cellular biochemistry

External Links

Snippet

To examine the possible role of basic fibroblast growth factor (FGF) in regulating the effects of TNFα, we tested the effect of FGF on TNFα-mediated PGE 2 production and TNFα receptor expression in human fibroblasts. We found that, while FGF alone had no effect on …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Similar Documents

Publication Publication Date Title
Mortensen et al. Interaction of recombinant IL-1 and recombinant tumor necrosis factor in the induction of mouse acute phase proteins.
Martínez et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages
Dignass et al. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor β
Seckinger et al. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor.
Higuchi et al. TNF induces internalization of the p60 receptor and shedding of the p80 receptor.
Cooper et al. IL-1 activity is reduced in psoriatic skin. Decreased IL-1 alpha and increased nonfunctional IL-1 beta.
Elias et al. A synergistic interaction of IL-6 and IL-1 mediates the thymocyte-stimulating activity produced by recombinant IL-1-stimulated fibroblasts.
Deleuran et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage‐pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor α
Elias et al. Cytokine networks in the regulation of inflammation and fibrosis in the lung
Chantry et al. Modulation of cytokine production by transforming growth factor-beta.
Akatsu et al. Role of prostaglandins in interleukin‐1‐induced bone resorption in mice in vitro
Porteu et al. Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils.
Leeb et al. Regulation of migration of human colonic myofibroblasts
Chandrasekhar et al. Induction of interleukin‐1 receptors on chondrocytes by fibroblast growth factor: a possible mechanism for modulation of interleukin‐1 activity
Brennan et al. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action
Heilig et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease
Feldmann et al. Cytokine blockade in rheumatoid arthritis
Eskay et al. Interleukin-1 alpha and tumor necrosis factor-alpha differentially regulate enkephalin, vasoactive intestinal polypeptide, neurotensin, and substance P biosynthesis in chromaffin cells.
Bonner et al. Basic fibroblast growth factor induces expression of the PDGF receptor-alpha on human bronchial smooth muscle cells
Johnson et al. Platelet-derived growth factor: A potentially important cytokine in glomerular disease
Burch et al. The kallikrein-kininogen-kinin system in chronic inflammation
Millet et al. The neuropeptide calcitonin gene-related peptide inhibits TNF-α but poorly induces IL-6 production by fetal rat osteoblasts
Hattori et al. Tumor necrosis factor (TNF) stimulates the production of nerve growth factor in fibroblasts via the 55‐kDa type 1 TNF receptor
Yoshinaga et al. Detection of inflammatory cytokines in psoriatic skin
Monick et al. Dexamethasone inhibits IL-1 and TNF activity in human lung fibroblasts without affecting IL-1 or TNF receptors